Recurrent Malignant Glioma (Oncology) - Drugs in Development, 2021
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma – Drugs In Development, 2021, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.
Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 1 molecules, respectively.
Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology). - The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
The US surgical procedures market is projected to reach 122,881.5 thousand procedures by 2027 from 105,814.5 thousand procedures in 2022, at a CAGR of 3.0% during the forecast period. The growth of this market is mainly attributed to the growing prevalence of cancer, rise in chronic diseases, increased investment in health facilities, technological...
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Drugs In Development, 2022, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape. Leiomyosarcoma...
The global pancreatic cancer therapeutics and diagnostics market is estimated to be USD 3,689.61 million in 2021 and is expected to reach USD 5,656.58 million by 2027, registering a CAGR of 7.43% from 2022 to 2027. The outbreak of COVID-19 significantly reduced hospital and healthcare services, impacting the pancreatic cancer therapeutics...
200 pages •
By The Business Research Company
• May 2022
Major players in the live cell imaging market are Leica Microsystems, Olympus Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc, GE Healthcare, Carl Zeiss Meditec AG, Becton Dickinson, and Company, Molecular Devices LLC, Bruker Corporation, and Sartorius AG. The global live cell imaging market is expected to grow from $3.41 billion...
Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Drugs In Development, 2022, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Fibrosarcoma...
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Toll Like Receptor 8 - Drugs In Development, 2022’; Toll Like Receptor 8 (CD288 or TLR8) pipeline...
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 184.108.40.206) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Histone Deacetylase 4 - Drugs In Development, 2022’; Histone Deacetylase...
120 pages •
By Infiniti Research Limited
• Mar 2022
Global Cancer Biologics Market 2022-2026 The analyst has been monitoring the cancer biologics market and it is poised to grow by $ 34.97 bn during 2022-2026 progressing at a CAGR of 8.91% during the forecast period. Our report on the cancer biologics market provides a holistic analysis, market size and forecast, trends,...
The gastrointestinal stent market is expected to reach USD 600 million by 2026 from USD 457 million in 2021, at a CAGR of 5.6 % during the forecast period of 2021 to 2026. Gastrointestinal (GI) stents are designed for palliative therapy for various diseases causing obstruction in the GI tract.GI stents have a major role in the recanalization...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.